{"id":194331,"date":"2026-08-10T15:45:12","date_gmt":"2026-08-10T10:15:12","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=194331"},"modified":"2026-08-10T15:45:15","modified_gmt":"2026-08-10T10:15:15","slug":"pros-cons-investing-granules-share","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/pros-cons-investing-granules-share\/","title":{"rendered":"Granules India Share: Pros and Cons Every Investor Must Know in 2026"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Granules India share CMP approx Rs 685. 52-week high Rs 865, low Rs 470. Market Cap Rs 16,650 Cr. P\/E ratio 22.66x.<\/em><\/p>\n<div style=\"background: #F0F7FF; border-left: 4px solid #1F4E79; border-radius: 6px; padding: 14px 18px; margin: 18px 0;\">\n<p style=\"margin: 0 0 8px 0; font-weight: bold; color: #1f4e79;\">Quick Answer<\/p>\n<ul style=\"margin: 0; padding-left: 20px; color: #333;\">\n<li>Granules India share at 22.66x PE with 16.66% ROE \u2014 India&#8217;s largest paracetamol and metformin API manufacturer<\/li>\n<li>World&#8217;s 2nd-largest paracetamol API producer; also metformin, ibuprofen, and guaifenesin API for global pharma<\/li>\n<li>Key strength: vertically integrated from API to finished dosage form \u2014 higher margins than pure API companies<\/li>\n<\/ul>\n<\/div>\n<p>Is the Granules India share a good investment in 2026? This article provides a data-driven analysis of Granules India share pros and cons \u2014 covering business strengths, valuation, growth drivers, and key risks \u2014 based on live data from 7 August 2026.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=granules-india-pros-cons\"><strong>Click Here \u2014 Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-granules-share\/#About_Granules_India\" title=\"About Granules India\">About Granules India<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-granules-share\/#Key_Financial_Snapshot_Granules_India_Share\" title=\"Key Financial Snapshot: Granules India Share\">Key Financial Snapshot: Granules India Share<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-granules-share\/#Top_5_Pros_of_Granules_India_Share\" title=\"Top 5 Pros of Granules India Share\">Top 5 Pros of Granules India Share<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-granules-share\/#1_Worlds_2nd-Largest_Paracetamol_Producer_%E2%80%94_Global_API_Volume_Scale_Advantage\" title=\"1. World&#8217;s 2nd-Largest Paracetamol Producer \u2014 Global API Volume Scale Advantage\">1. World&#8217;s 2nd-Largest Paracetamol Producer \u2014 Global API Volume Scale Advantage<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-granules-share\/#2_Vertical_Integration_From_API_to_Finished_Dosage_%E2%80%94_Higher_Margin_Capture\" title=\"2. Vertical Integration From API to Finished Dosage \u2014 Higher Margin Capture\">2. Vertical Integration From API to Finished Dosage \u2014 Higher Margin Capture<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-granules-share\/#3_Metformin_Ibuprofen_and_Guaifenesin_%E2%80%94_Diversified_Generic_Pharma_Product_Base\" title=\"3. Metformin, Ibuprofen, and Guaifenesin \u2014 Diversified Generic Pharma Product Base\">3. Metformin, Ibuprofen, and Guaifenesin \u2014 Diversified Generic Pharma Product Base<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-granules-share\/#4_1666_Percent_ROE_With_Moderate_Debt_%E2%80%94_Quality_API_Manufacturing_Returns\" title=\"4. 16.66 Percent ROE With Moderate Debt \u2014 Quality API Manufacturing Returns\">4. 16.66 Percent ROE With Moderate Debt \u2014 Quality API Manufacturing Returns<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-granules-share\/#5_US_Finished_Dosage_Business_Growing_%E2%80%94_Higher_Margin_ANDA_Formulations\" title=\"5. US Finished Dosage Business Growing \u2014 Higher Margin ANDA Formulations\">5. US Finished Dosage Business Growing \u2014 Higher Margin ANDA Formulations<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-granules-share\/#Key_Cons_of_Granules_India_Share\" title=\"Key Cons of Granules India Share\">Key Cons of Granules India Share<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-granules-share\/#1_Paracetamol_API_Price_Volatility_%E2%80%94_Commodity_Input_Creating_Revenue_Cycle_Risk\" title=\"1. Paracetamol API Price Volatility \u2014 Commodity Input Creating Revenue Cycle Risk\">1. Paracetamol API Price Volatility \u2014 Commodity Input Creating Revenue Cycle Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-granules-share\/#2_Chinese_Paracetamol_API_Competition_%E2%80%94_Price_Undercutting_From_Scale_Manufacturers\" title=\"2. Chinese Paracetamol API Competition \u2014 Price Undercutting From Scale Manufacturers\">2. Chinese Paracetamol API Competition \u2014 Price Undercutting From Scale Manufacturers<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-granules-share\/#3_US_Generic_Finished_Dosage_Price_Erosion_%E2%80%94_Standard_ANDA_Competition\" title=\"3. US Generic Finished Dosage Price Erosion \u2014 Standard ANDA Competition\">3. US Generic Finished Dosage Price Erosion \u2014 Standard ANDA Competition<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-granules-share\/#4_Debt-to-Equity_of_037x_%E2%80%94_API_Manufacturing_Capital_Intensity_Creating_Leverage\" title=\"4. Debt-to-Equity of 0.37x \u2014 API Manufacturing Capital Intensity Creating Leverage\">4. Debt-to-Equity of 0.37x \u2014 API Manufacturing Capital Intensity Creating Leverage<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-granules-share\/#Is_Granules_India_Share_a_Good_Investment_in_2026\" title=\"Is Granules India Share a Good Investment in 2026?\">Is Granules India Share a Good Investment in 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-granules-share\/#Key_Risks_Before_Buying_Granules_India_Share\" title=\"Key Risks Before Buying Granules India Share\">Key Risks Before Buying Granules India Share<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-granules-share\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-granules-share\/#Frequently_Asked_Questions_%E2%80%94_Granules_India_Share\" title=\"Frequently Asked Questions \u2014 Granules India Share\">Frequently Asked Questions \u2014 Granules India Share<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-granules-share\/#What_are_the_main_pros_of_Granules_India_share\" title=\"What are the main pros of Granules India share?\">What are the main pros of Granules India share?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-granules-share\/#What_are_the_risks\" title=\"What are the risks?\">What are the risks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-granules-share\/#Is_Granules_India_share_a_good_investment\" title=\"Is Granules India share a good investment?\">Is Granules India share a good investment?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-granules-share\/#What_is_the_52-week_range\" title=\"What is the 52-week range?\">What is the 52-week range?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-granules-share\/#What_is_paracetamol_API_and_why_is_Granules_Indias_volume_scale_important\" title=\"What is paracetamol API and why is Granules India&#8217;s volume scale important?\">What is paracetamol API and why is Granules India&#8217;s volume scale important?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-granules-share\/#How_does_Granules_India_compare_to_Divis_Laboratories_in_pharma_API\" title=\"How does Granules India compare to Divi&#8217;s Laboratories in pharma API?\">How does Granules India compare to Divi&#8217;s Laboratories in pharma API?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"About_Granules_India\"><\/span><strong>About Granules India<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Granules India Limited (NSE: GRANULES) is a Hyderabad-based pharmaceutical company founded in 1984. India&#8217;s largest paracetamol (acetaminophen) API producer and the world&#8217;s second-largest, it manufactures pharmaceutical ingredients (APIs) and finished dosage forms (tablets, capsules) for paracetamol, metformin, ibuprofen, and guaifenesin \u2014 supplied to global generic pharmaceutical companies across USA, Europe, and emerging markets.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Financial_Snapshot_Granules_India_Share\"><\/span><strong>Key Financial Snapshot: Granules India Share<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Parameter<\/th>\n<th>Details<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Company<\/td>\n<td><a href=\"https:\/\/univest.in\/stocks\/granules\/granules-india-ltd-share-price-today\">Granules India<\/a><\/td>\n<\/tr>\n<tr>\n<td>NSE Symbol<\/td>\n<td>GRANULES<\/td>\n<\/tr>\n<tr>\n<td>Sector<\/td>\n<td>Pharma API Formulations<\/td>\n<\/tr>\n<tr>\n<td>CMP (Approx)<\/td>\n<td>Rs 685<\/td>\n<\/tr>\n<tr>\n<td>52-Week High<\/td>\n<td>Rs 865<\/td>\n<\/tr>\n<tr>\n<td>52-Week Low<\/td>\n<td>Rs 470<\/td>\n<\/tr>\n<tr>\n<td>Market Cap<\/td>\n<td>Rs 16,650 Cr<\/td>\n<\/tr>\n<tr>\n<td>P\/E Ratio<\/td>\n<td>22.66x<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><em>Data approximate. Verify at <a href=\"https:\/\/www.nseindia.com\" rel=\"nofollow noopener\" target=\"_blank\">nseindia.com<\/a>.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Top_5_Pros_of_Granules_India_Share\"><\/span><strong>Top 5 Pros of Granules India Share<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"1_Worlds_2nd-Largest_Paracetamol_Producer_%E2%80%94_Global_API_Volume_Scale_Advantage\"><\/span><strong>1. World&#8217;s 2nd-Largest Paracetamol Producer \u2014 Global API Volume Scale Advantage<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Granules India share benefits from world-scale paracetamol API manufacturing \u2014 producing hundreds of thousands of tonnes annually for global pharmaceutical companies. This volume scale provides cost efficiency that smaller Indian API producers cannot match, enabling competitive pricing while maintaining margins.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"2_Vertical_Integration_From_API_to_Finished_Dosage_%E2%80%94_Higher_Margin_Capture\"><\/span><strong>2. Vertical Integration From API to Finished Dosage \u2014 Higher Margin Capture<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Granules India&#8217;s vertical integration allows it to convert its own paracetamol API into finished tablets and capsules \u2014 capturing both API manufacturing margin and finished dosage formulation margin in a single value chain. This integration advantage improves EBITDA margin above pure API-only manufacturers.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"3_Metformin_Ibuprofen_and_Guaifenesin_%E2%80%94_Diversified_Generic_Pharma_Product_Base\"><\/span><strong>3. Metformin, Ibuprofen, and Guaifenesin \u2014 Diversified Generic Pharma Product Base<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Beyond paracetamol, Granules India manufactures metformin (diabetes), ibuprofen (pain and inflammation), and guaifenesin (cough and cold) APIs \u2014 diversifying from single-product dependency and providing multiple growing generic pharmaceutical market exposures.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"4_1666_Percent_ROE_With_Moderate_Debt_%E2%80%94_Quality_API_Manufacturing_Returns\"><\/span><strong>4. 16.66 Percent ROE With Moderate Debt \u2014 Quality API Manufacturing Returns<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>At 16.66 percent ROE with debt-to-equity of 0.37x, Granules India delivers solid returns for an API manufacturing company \u2014 reflecting its volume scale and vertical integration advantages over smaller generic API peers.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"5_US_Finished_Dosage_Business_Growing_%E2%80%94_Higher_Margin_ANDA_Formulations\"><\/span><strong>5. US Finished Dosage Business Growing \u2014 Higher Margin ANDA Formulations<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Granules India&#8217;s US finished dosage (tablet and capsule) ANDA business is growing \u2014 providing higher-margin branded generic equivalents versus bulk API commodity sales. US finished dose formulations command 3 to 5x the margin of API-only supply.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Cons_of_Granules_India_Share\"><\/span><strong>Key Cons of Granules India Share<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"1_Paracetamol_API_Price_Volatility_%E2%80%94_Commodity_Input_Creating_Revenue_Cycle_Risk\"><\/span><strong>1. Paracetamol API Price Volatility \u2014 Commodity Input Creating Revenue Cycle Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Paracetamol API is a globally traded commodity with Chinese manufacturers creating pricing pressure when capacity expands. Global paracetamol API prices can decline 30 to 50 percent in oversupply cycles \u2014 compressing Granules India&#8217;s API revenue even when volumes remain stable.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"2_Chinese_Paracetamol_API_Competition_%E2%80%94_Price_Undercutting_From_Scale_Manufacturers\"><\/span><strong>2. Chinese Paracetamol API Competition \u2014 Price Undercutting From Scale Manufacturers<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>China&#8217;s AAPH (para-aminophenol \u2014 the paracetamol precursor) chemical supply advantage enables Chinese paracetamol API manufacturers to produce at lower costs than Indian producers. Chinese paracetamol API price competition is the primary structural margin threat.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"3_US_Generic_Finished_Dosage_Price_Erosion_%E2%80%94_Standard_ANDA_Competition\"><\/span><strong>3. US Generic Finished Dosage Price Erosion \u2014 Standard ANDA Competition<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Granules India&#8217;s US ANDA finished dosage products face price erosion as multiple filers launch competing generic products. Standard OTC generic products (paracetamol tablets, ibuprofen tablets) have already experienced 60 to 80 percent US price erosion from ANDA competition.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"4_Debt-to-Equity_of_037x_%E2%80%94_API_Manufacturing_Capital_Intensity_Creating_Leverage\"><\/span><strong>4. Debt-to-Equity of 0.37x \u2014 API Manufacturing Capital Intensity Creating Leverage<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Granules India&#8217;s API and formulation manufacturing requires significant plant and equipment investment \u2014 creating 0.37x debt-to-equity that adds financial cost sensitivity to interest rate cycles.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Use the Univest Screener to Analyse Stocks for Free<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Is_Granules_India_Share_a_Good_Investment_in_2026\"><\/span><strong>Is Granules India Share a Good Investment in 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Granules India share is India&#8217;s quality pharmaceutical API investment at reasonable PE \u2014 world-scale paracetamol API leadership and vertical integration are genuine advantages. Chinese API competition and US generic price erosion are the structural constraints. Consider as quality pharma API core allocation.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_Before_Buying_Granules_India_Share\"><\/span><strong>Key Risks Before Buying Granules India Share<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li>Chinese paracetamol API price dumping compressing Granules India&#8217;s API selling prices<\/li>\n<li>US generic ANDA finished dosage price erosion reducing formulation business margins<\/li>\n<li>Para-aminophenol feedstock price spike increasing paracetamol production costs<\/li>\n<li>USFDA warning letter on Granules manufacturing facility impacting US finished dosage sales<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Granules India share offers world&#8217;s 2nd-largest paracetamol producer \u2014 global api volume scale advantage as its primary investment case. Weigh it against paracetamol api price volatility \u2014 commodity input creating revenue cycle risk and the risks above before investing. Use the Univest Screener and consult a SEBI-registered advisor.<\/p>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"https:\/\/apps.apple.com\/in\/app\/univest-stock-market-research\/id1576403520\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"https:\/\/play.google.com\/store\/apps\/details?id=com.univest.stockmarket\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Granules India share price live.<\/em><\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data from publicly available sources. Approximate as of 7 Aug 2026. Verify on nseindia.com and bseindia.com. Not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_%E2%80%94_Granules_India_Share\"><\/span><strong>Frequently Asked Questions \u2014 Granules India Share<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_main_pros_of_Granules_India_share\"><\/span><strong>What are the main pros of Granules India share?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> World&#8217;s 2nd-largest paracetamol API producer with volume scale advantage, vertical integration from API to finished dosage capturing multi-layer margins, metformin, ibuprofen, and guaifenesin diversifying beyond paracetamol, 16.66% ROE from API scale efficiency, and US finished dosage ANDA business growing at higher margins.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_risks\"><\/span><strong>What are the risks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Paracetamol API price volatility from Chinese manufacturer oversupply, US generic finished dosage price erosion from ANDA competition, Chinese API cost advantage structural threat, and debt-to-equity 0.37x adding interest rate sensitivity. Monitor quarterly paracetamol API prices and US ANDA launch pipeline.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Granules_India_share_a_good_investment\"><\/span><strong>Is Granules India share a good investment?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Quality pharma API manufacturer at reasonable PE. Consider as pharma API core allocation. Consult a SEBI-registered advisor. Not investment advice.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_52-week_range\"><\/span><strong>What is the 52-week range?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> 52-week high approximately Rs 865, low Rs 470. Current Rs 685. Verify at nseindia.com.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_paracetamol_API_and_why_is_Granules_Indias_volume_scale_important\"><\/span><strong>What is paracetamol API and why is Granules India&#8217;s volume scale important?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Paracetamol API (acetaminophen) is the world&#8217;s most consumed pain reliever active pharmaceutical ingredient \u2014 used in Tylenol, Crocin, Dolo, and hundreds of global OTC and prescription pain relief medicines. The world produces approximately 180,000 tonnes annually, with China and India as the largest producers. Granules India produces tens of thousands of tonnes per year at its Hyderabad plants \u2014 giving it scale economies in raw material procurement, energy costs, and manufacturing efficiency that smaller manufacturers cannot replicate.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_does_Granules_India_compare_to_Divis_Laboratories_in_pharma_API\"><\/span><strong>How does Granules India compare to Divi&#8217;s Laboratories in pharma API?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Divi&#8217;s Laboratories focuses on complex API (Sartan series, custom synthesis, Divi&#8217;s DSN nutraceuticals) with better ROE (~24%) and higher margins from complex molecule specialisation. Granules India focuses on high-volume commodity API (paracetamol, metformin) with lower margins but better volume scale. For quality complex API specialisation, Divi&#8217;s is preferred. For volume-scale commodity API with vertical integration, Granules India is the choice. Both are quality pharma API investments at different segments of the value chain.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Granules India share pros and cons: world&#8217;s 2nd-largest paracetamol API producer at reasonable PE with vertical integration advantage analysed for 2026.<\/p>\n","protected":false},"author":28,"featured_media":194328,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802],"class_list":["post-194331","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["194328"],"_edit_lock":["1786356917:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["76"],"rank_math_title":["Granules India Share Pros and Cons 2026 | GRANULES Pharma API Analysis"],"rank_math_description":["Granules India share pros and cons: global paracetamol and pharma API leader at 22.66x PE with 16.66% ROE versus US generic competition and API price volatility."],"rank_math_focus_keyword":["Granules India Share"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["35519"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/08\/pros-cons-investing-granules-share.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/194331","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=194331"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/194331\/revisions"}],"predecessor-version":[{"id":194562,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/194331\/revisions\/194562"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/194328"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=194331"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=194331"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=194331"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}